Tag: Sanofi
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Study scheduled to commence next week.
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...
"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate
The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
Auvi-Q Takes Center Stage at School Nurse Conference
One example of the changing market dynamics for epinephrine auto-injectors in light of recent developments.
Mylan’s Chairman Was Paid $97.6 Million
Despite 2016 being a year when everything seemed to implode for the marketer of EpiPen.
Sanofi Files Suit Against Mylan for Anti-Competitive EpiPen Strategy
More legal troubles for the embattled marketer of EpiPen.
Auvi-Q Goes On Sale Today with a Bold Pricing and Distribution...
Innovation and participation by insurers will be key to the successful reintroduction of the device.
